Using CRISPR to Modulate Gene Expression

RARECast - A podcast by RARECast - Giovedì

Categorie:

Amber Salzman, CEO of Epicrispr Biotechnologies, discusses the company’s one-and-done therapies work to target the epigenome, its lead program in FSHD, and the broader applications for its therapeutic approach.

Visit the podcast's native language site